

HOUSE COMMITTEE OF REFERENCE AMENDMENT

Committee on Health & Insurance.

HB22-1370 be amended as follows:

1 Amend printed bill, page 12, strike lines 10 through 27.

2 Strike pages 13 through 17.

3 Page 18, strike lines 1 through 21 and substitute:

4       **"10-16-155. Prescription drugs - rebates - consumer cost  
5 reduction - point of sale - study - report - rules - definitions.**

6 (1) (a) AS USED IN THIS SECTION, UNLESS THE CONTEXT OTHERWISE  
7 REQUIRES:

8       (I) "DISCOUNT" MEANS PRICE REDUCTIONS OR CONCESSIONS,  
9 INCLUDING BASE PRICE CONCESSIONS OR OTHER CONTRACTUAL  
10 AGREEMENTS MADE BY A MANUFACTURER OR ITS AFFILIATE, THAT REDUCE  
11 PAYMENT OR LIABILITY FOR PRESCRIPTION DRUGS INCLUDING A  
12 REDUCTION IN THE TOTAL AMOUNT PAID FOR PRESCRIPTION DRUGS,  
13 WITHOUT REGARD TO PERFORMANCE, VOLUME, OR UTILIZATION OF THE  
14 DRUGS AND ALL OTHER COMPENSATION THAT REDUCES PAYMENT OR  
15 LIABILITY FOR PRESCRIPTION DRUGS. "DISCOUNT" DOES NOT INCLUDE A  
16 REBATE.

17       (II) "HEALTH INSURER" MEANS A CARRIER:

18       (A) AS DEFINED IN SECTION 10-16-102 (8); AND  
19       (B) AS DEFINED IN SECTION 24-50-603 (2).

20       (III) "MANUFACTURER" HAS THE SAME MEANING AS SET FORTH IN  
21 SECTION 10-16-1401 (16).

22       (IV) "PRESCRIPTION DRUG" HAS THE SAME MEANING AS SET FORTH  
23 IN SECTION 12-280-103 (42); EXCEPT THAT THE TERM INCLUDES ONLY  
24 PRESCRIPTION DRUGS THAT ARE INTENDED FOR HUMAN USE.

25       (V) "REBATE" MEANS ALL PRICE CONCESSIONS MADE BY A  
26 MANUFACTURER OR ITS AFFILIATE THAT ACCRUE TO A PBM OR ITS HEALTH  
27 INSURER CLIENT OR ITS AFFILIATE, INCLUDING CREDITS OR INCENTIVES  
28 THAT ARE BASED ON ACTUAL OR ESTIMATED UTILIZATION OF  
29 PRESCRIPTION DRUGS; THAT RESULT IN THE PLACEMENT OF A  
30 PRESCRIPTION DRUG IN A PREFERRED DRUG LIST OR FORMULARY OR  
31 PREFERRED FORMULARY POSITION; OR THAT ARE ASSOCIATED WITH  
32 CLAIMS ADMINISTERED ON BEHALF OF AN INSURER CLIENT. "REBATE"  
33 ALSO INCLUDES CREDITS, INCENTIVES, REFUNDS, AND ALL OTHER  
34 COMPENSATION THAT IS PERFORMANCE-BASED. "REBATE" DOES NOT  
35 INCLUDE A DISCOUNT.

36       (b) THE COMMISSIONER MAY PROMULGATE RULES TO FURTHER  
37 DEFINE "DISCOUNT" AND "REBATE" FOR PURPOSES OF THIS SECTION.

38       (2) FOR EACH HEALTH BENEFIT PLAN ISSUED OR RENEWED ON OR

1 AFTER JANUARY 1, 2024, A HEALTH INSURER SHALL ENSURE THAT ONE  
2 HUNDRED PERCENT OF DISCOUNTS RECEIVED OR TO BE RECEIVED FROM A  
3 MANUFACTURER IN CONNECTION WITH DISPENSING OR ADMINISTERING  
4 PRESCRIPTION DRUGS INCLUDED IN THE HEALTH INSURER'S FORMULARY  
5 FOR THAT PLAN YEAR ARE USED TO REDUCE COSTS.

6 (3) FOR EACH HEALTH BENEFIT PLAN ISSUED OR RENEWED ON OR  
7 AFTER JANUARY 1, 2024, A HEALTH INSURER SHALL ENSURE THAT:

8 (a) ONE HUNDRED PERCENT OF THE ESTIMATED REBATES RECEIVED  
9 OR TO BE RECEIVED IN CONNECTION WITH DISPENSING OR ADMINISTERING  
10 PRESCRIPTION DRUGS INCLUDED IN THE HEALTH INSURER'S FORMULARY  
11 FOR THAT PLAN YEAR ARE USED TO REDUCE POLICYHOLDER COSTS;

12 (b) FOR SMALL GROUP AND LARGE GROUP HEALTH BENEFIT PLANS,  
13 ALL REBATES ARE USED TO REDUCE EMPLOYER OR INDIVIDUAL EMPLOYEE  
14 COSTS; AND

15 (c) FOR INDIVIDUAL HEALTH BENEFIT PLANS, ALL REBATES ARE  
16 USED TO REDUCE CONSUMER PREMIUMS AND OUT-OF-POCKET COSTS FOR  
17 PRESCRIPTION DRUGS AND THAT HEALTH INSURERS WILL MAXIMIZE THE  
18 USE OF REBATES TO REDUCE CONSUMER OUT-OF-POCKET COSTS AT THE  
19 POINT OF SALE NOT TO EXCEED THE CONSUMER'S ACTUAL OUT-OF-POCKET  
20 COSTS FOR THE PRESCRIPTION DRUG IF THE USE OF SUCH REBATES WILL  
21 NOT:

22 (I) INCREASE PREMIUMS;  
23 (II) CHANGE THE ACTUARIAL VALUE OF THE PLAN INCONSISTENT  
24 WITH FEDERAL AND STATE REQUIREMENTS; OR  
25 (III) OTHERWISE RESULT IN AN IMPACT THAT IS NOT IN THE BEST  
26 INTEREST OF CONSUMERS.

27 (4) (a) ON OR BEFORE JUNE 1, 2023, THE DIVISION SHALL CONDUCT  
28 AND COMPLETE A STUDY TO EVALUATE HOW REBATES MAY BE APPLIED IN  
29 THE INDIVIDUAL MARKET TO REDUCE A COVERED PERSON'S  
30 OUT-OF-POCKET COSTS AT THE POINT OF SALE OR TO REDUCE  
31 OUT-OF-POCKET COSTS IN PRESCRIPTION DRUG TIERS, TAKING INTO  
32 CONSIDERATION THE FOLLOWING FACTORS:

33 (I) PREMIUM IMPACTS;  
34 (II) CHANGES IN THE PLAN'S ACTUARIAL VALUE; AND  
35 (III) OTHER POTENTIAL IMPACTS TO CONSUMERS.

36 (b) REGARDLESS OF THE RESULTS OF THE STUDY, A HEALTH  
37 INSURER SHALL COMPLY WITH SUBSECTION (3) OF THIS SECTION.

38 (c) THE DIVISION MAY CONTRACT WITH A THIRD PARTY TO  
39 CONDUCT THE STUDY REQUIRED BY THIS SUBSECTION (4). THE  
40 COMMISSIONER IS NOT REQUIRED TO COMPLY WITH THE "PROCUREMENT  
41 CODE", ARTICLES 101 TO 112 OF TITLE 24, FOR THE PURPOSES OF THIS  
42 SECTION.

43 (5) EACH HEALTH INSURER SHALL REPORT ANNUALLY:

44 (a) IN A FORM AND MANNER DETERMINED BY THE COMMISSIONER,  
45 DATA DEMONSTRATING THAT ALL DISCOUNTS AND REBATES RECEIVED BY

1     HEALTH INSURERS ARE USED TO REDUCE COSTS FOR POLICYHOLDERS IN  
2     COMPLIANCE WITH THIS SECTION. THE COMMISSIONER MAY USE DISCOUNT  
3     AND REBATE DATA SUBMITTED BY HEALTH INSURERS TO THE ALL-PAYER  
4     HEALTH CLAIMS DATABASE DESCRIBED IN SECTION 25.5-1-204 TO THE  
5     EXTENT SUCH DATA ARE AVAILABLE FROM THE ALL-PAYER HEALTH  
6     CLAIMS DATABASE.

7                 (b) AN ACTUARIAL CERTIFICATION THAT ATTESTS THAT:  
8                     (I) THE HEALTH INSURER AND PBM ARE IN COMPLIANCE WITH  
9                     SUBSECTIONS (2) AND (3) OF THIS SECTION; AND  
10                    (II) THE DATA REPORTED AS REQUIRED BY THIS SECTION ARE  
11                    ACCURATE.

12                 (6) THE DIVISION MAY USE DATA FROM THE DEPARTMENT OF  
13     HEALTH CARE POLICY AND FINANCING, THE ALL-PAYER HEALTH CLAIMS  
14     DATABASE DESCRIBED IN SECTION 25.5-1-204, AND OTHER SOURCES TO  
15     VERIFY THAT A HEALTH INSURER AND PBM ARE IN COMPLIANCE WITH THIS  
16     SECTION.

17                 (7) INFORMATION SUBMITTED BY THE HEALTH INSURERS AND  
18     PBMs TO THE DIVISION IN ACCORDANCE WITH THIS SECTION IS SUBJECT TO  
19     PUBLIC INSPECTION ONLY TO THE EXTENT ALLOWED UNDER THE  
20     "COLORADO OPEN RECORDS ACT", PART 2 OF ARTICLE 72 OF TITLE 24,  
21     AND IN NO CASE SHALL TRADE-SECRET, CONFIDENTIAL, OR PROPRIETARY  
22     INFORMATION BE DISCLOSED TO ANY PERSON WHO IS NOT OTHERWISE  
23     AUTHORIZED TO ACCESS SUCH INFORMATION.

24                 (8) THIS SECTION DOES NOT PROHIBIT A HEALTH INSURER FROM  
25     DECREASING COST-SHARING AMOUNTS OR PREMIUMS BY AN AMOUNT  
26     GREATER THAN THE AMOUNT REQUIRED IN SUBSECTION (2) OR (3) OF THIS  
27     SECTION.

28                 (9) THE REQUIREMENTS OF SUBSECTIONS (2), (3), AND (5) OF THIS  
29     SECTION APPLY TO A SELF-FUNDED HEALTH BENEFIT PLAN AND ITS PLAN  
30     MEMBERS ONLY IF THE ENTITY THAT PROVIDES THE PLAN ELECTS TO BE  
31     SUBJECT TO SUBSECTIONS (2), (3), AND (5) OF THIS SECTION FOR ITS  
32     MEMBERS IN COLORADO.

33                 (10) THE COMMISSIONER SHALL PROMULGATE RULES TO  
34     IMPLEMENT AND ENFORCE THIS SECTION.".

\*\*\* \* \* \* \*